GlassScriptPhysician profile
Eileen Aguilar
NPI 1427628353
$3,521.33
in general payments reported to CMS, 2019-2025
22 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,450 · 2023: $1,754 · 2024: $192 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $599.59 | 2022-2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $585.52 | 2022-2023 | |
| Lilly USA, LLC | $405.65 | 2022-2023 | Jardiance, Baqsimi, Lyumjev |
| Novo Nordisk INC | $361.78 | 2022-2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $252.20 | 2022-2023 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $215.33 | 2022-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $151.90 | 2022-2023 | Tepezza |
| Amgen INC. | $146.71 | 2023 | Prolia, Evenity |
| Tandem Diabetes Care, INC. | $145.15 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Embecta Corp. | $108.77 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Abbvie INC. | $105.95 | 2022-2023 | Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $100.96 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.42 | 2022-2023 | Synjardy, Jardiance, Tradjenta |
| Radius Health, INC. | $57.26 | 2023 | |
| Amneal Pharmaceuticals LLC | $47.29 | 2023 | Unithroid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.06 | 2022-2023 | Minimed 770g |
| Amryt Pharma Holdings LTD | $26.44 | 2023 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $22.98 | 2023 | |
| Becton, Dickinson and Company | $22.22 | 2022 | |
| Recordati_rare_diseases_inc. | $19.94 | 2023 | Isturisa, Signifor Lar |
| Pfizer INC. | $18.68 | 2022 | |
| Nevro Corp. | $16.53 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Aguilar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.